CoChat

Therapeutic cancer vaccines

Saxena, Mansi, van der Burg, Sjoerd H., Melief, Cornelis J. M., Bhardwaj, Nina · 2021 · Nature reviews. Cancer

The DOI matches its Crossref record; 286 of the 286 references it cites were found in a registry or an index.

Abstract

Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better understanding of the breadth of tumour-associated antigens, the native immune response and development of novel technologies for antigen delivery has facilitated improved vaccine design. The goal of therapeutic cancer vaccines is to induce tumour regression, eradicate minimal residual disease, establish lasting antitumour memory and avoid non-specific or adverse reactions. However, tumour-induced immunosuppression and immunoresistance pose significant challenges to achieving this goal. In this Review, we deliberate on how to improve and expand the antigen repertoire for vaccines, consider developments in vaccine platforms and explore antigen-agnostic in situ vaccines. Furthermore, we summarize the reasons for failure of cancer vaccines in the past and provide an overview of various mechanisms of resistance posed by the tumour. Finally, we propose strategies for combining suitable vaccine platforms with novel immunomodulatory approaches and standard-of-care treatments for overcoming tumour resistance and enhancing clinical efficacy.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41568-021-00346-0

Cites

286 of 286 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 286 references

Research works printed but not linked: 1

  1. Nalley, C. I-SPY 2 trial explores immune checkpoint plus PARP inhibitors in breast cancer. Oncol. Times 42, 37 (2020).

Cited by

See all 1,581

Metadata

Authors
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N.
Affiliations
  • Tisch Cancer Institute (US)
  • ISA Pharmaceuticals (Netherlands) (NL)
  • Parker Institute for Cancer Immunotherapy (US)
Corresponding author
Bhardwaj, Nina
Venue
Nature reviews. Cancer
Published
2021-04-27
Volume
21
Issue
6
Pages
360-378
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W4206384730
Cited by
1,581
References
286
Citations by year
2026: 204 · 2025: 371 · 2024: 396 · 2023: 335 · 2022: 220 · 2021: 51
FWCI
25.66
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature reviews. Cancer (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
Funders
  • National Cancer Institute (R01CA201189, R01CA249175)
  • National Institute of Allergy and Infectious Diseases (R01AI081848)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
therapeutic cancer vaccines, tumor-associated antigens, vaccine platforms, antigen delivery, in situ vaccine, tumor immunosuppression, immunoresistance, tumor regression, minimal residual disease, combination immunotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic cancer vaccines. https://app.cochat.ai/papers/10.1038/s41568-021-00346-0
The paper
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021). Therapeutic cancer vaccines. Nature reviews. Cancer. https://doi.org/10.1038/s41568-021-00346-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.